Integrin α10β1 Selected MSCs – A Superior Therapeutic Approach

Time: 10:30 am
day: Day Two

Details:

  • Xintela’s integrin biomarker technology platform has potential to reach $10bn commercials through OA, GBM and TNBC

Speakers: